Aktie A222110 PANGEN BIOTECH INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen PanGen Biotech Inc.

Aktien

A222110

KR7222110009

A222110

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 27.06.2024 		% 5 Tage % 1. Jan.
4’950 KRW -5.71% Intraday Chart für PanGen Biotech Inc. -11.45% -28.05%
2023 PanGen Biotech Inc. meldet Ergebnis für das erste Quartal zum 31. März 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
PanGen Biotech Inc. agreed to acquire PANACEA Inc. from Invites Ventures Co., Ltd., and others
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
PanGen Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
PanGen Biotech Inc. announced that it has received KRW 3.2 billion in funding from Eugene Investment & Securities Co.,Ltd., Samsung Securities Co., Ltd.
PanGen Biotech Inc. announced that it expects to receive KRW 3.2 billion in funding from Eugene Investment & Securities Co.,Ltd., Samsung Securities Co., Ltd.
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.
PanGen Biotech Inc. announced that it has received KRW 9.99998571 billion in funding from Huons Co., Ltd. and another investor
PanGen Biotech Inc. announced that it expects to receive KRW 9.99998571 billion in funding from Huons Co., Ltd., and another investor
Huons Lab Forms Partnership with Pangen Biotech to Co-Develop Human Genetic Recombinant Hyaluronidase
PanGen Biotech Inc.(KOSDAQ:A222110) dropped from S&P Global BMI Index
CCM Duopharma Biotech Berhad completed the acquisition of 8.4% stake in PanGen Biotech Inc. from Chemical Company of Malaysia Berhad.
CCM Duopharma Biotech Berhad entered into agreement to acquire PanGen Biotech Inc. from Chemical Company of Malaysia Berhad for KRW 16.4 billion.
Chemical Companies In Talks To Sell Non Core Assets
PanGen Biotech Inc. announced that it has received KRW 18 billion in funding
PanGen Biotech Inc. announced that it expects to receive KRW 18 billion in funding
PanGen Biotech Inc.(KOSDAQ:A222110) added to S&P Global BMI Index
PanGen Biotech Inc. has completed an IPO in the amount of KRW 27.23 billion.
PanGen Biotech Inc. has filed an IPO in the amount of KRW 18.75 billion.
PanGen Biotech Inc. has withdrawn its IPO in the amount of KRW 35.40 billion.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A222110 Aktie
  4. Nachrichten PanGen Biotech Inc.
  5. Andere Sprachen